menu search

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
First patient dosed in Quoin’s single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy Recruitment and dosing continue in Quoin’s ongoing double blinded, placebo-controlled study of QRX003 for Netherton Syndrome Following successful public offering Quoin expects its cash runway will extend into 2H 2024 ASHBURN, Va., May 08, 2023 […] The post Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Res... Read More
Posted: May 8 2023, 21:00
Author Name: forextv
Views: 081724

Search within

Pages Search Results: